Key Takeaways
- Revenue guidance intact, back-end loaded: Management reaffirmed the ₹400 crores FY24 revenue target, with API contributing in Q3 and expanded MCC capacity in Q4.
- Standalone margin squeezed by people cost: Employee costs jumped to ₹14.73 crores (from ~₹12.8 cr in Q1) as manpower-based services and the new API facility added headcount; stabilization is promised from Q4.
- Consolidated margins held up on subsidiary strength: Sigachi US and MENA cleared customer stocks and picked up demand, offsetting the standalone margin decline.
- Ambitious 3-5 year growth target set: Management is looking at at least 25% top-line growth year-on-year over the next 3 to 5 years, driven by pharma and API.
- What to watch next quarter: Whether the API business scales toward the ~₹60 crore FY24 target, whether environmental clearance for CCS arrives in December, and whether employee cost as a percentage of sales begins to drop.
Revenue Trajectory & Back-End Loading
- ₹400 crores FY24 guidance reaffirmed: Management stated the target is easily achievable, with Q3 adding API revenue and Q4 adding expanded MCC capacity sales.
- API revenue target: The API subsidiary is expected to deliver ~₹40 crores in the remaining months to hit the ~₹60 crore FY24 target; management is fairly confident. Combined August and September revenue was ~₹7.5 crores.
- MCC expansion timing: Commissioning activities commence by the end of Q3 FY24; sales from the added capacity will reflect in Q4, with 25% of the added capacity in Q4 seen as a fair target.
- Food & nutrition ramp: Management expects good growth over the next couple of months and definitely in the next financial year, with volumes becoming more reasonable rather than small intermittent batches.
Sinha: "I would say that this in absolute terms would go up slightly, but overall I believe, the sales would increase and in percentage terms, this will drop at a later quarter."
Margin Dynamics
- Standalone margin decline: The major element was higher employee cost, which rose from ~₹12.8 crores in Q1 to ₹14.73 crores in Q2 due to O&M manpower-based services, OTC/generics manpower, and the acquired API facility adding headcount.
- Consolidated margin improvement: Subsidiaries Sigachi US and Sigachi MENA performed well, clearing customer stocks and picking up demand; the API subsidiary contributed but was not the main driver.
- Employee cost trajectory: Absolute employee cost may increase slightly beyond ₹14.72 crores because the acquired facility was not in books for all three months; stabilization is expected from Q4 FY24 onward, with the cost dropping as a percentage of sales at a later quarter.
- EBITDA margin comfort: Management stated it is comfortable on the positive side of 20% EBITDA all throughout.
Segment & Product Updates
| Segment | Trend | Commentary |
|---|---|---|
| MCC (core excipient) | ▬ Steady | Price grew modestly 1.07% YoY to ₹210.8/Kg; quantity grew 3.63% YoY to 7,307 MT in H1 FY24. Niche product with 60 grades. |
| API subsidiary | ▲ Ramping | Acquired Karnataka unit consolidated from August 1; integration ongoing. Target product lines and chemistry being firmed up; regulatory approvals from European Directorate and US FDA are key next steps. |
| Food & Nutrition | ▲ Building | Supplementary product line sold to existing cellulose customers needing label-claim ingredients. Focus is on bulk business across continents, not domestic. Product approvals take time; samples sometimes need resubmission. |
| CCS | ▼ Pre-revenue | Gujarat Microwax is the predominant leader; CCS has large imports. Sigachi's PLI application awaits environmental clearance, expected December 2023. Commissioning takes 18 months from clearance. |
- Management bandwidth: All segments are related diversification within the pharma ecosystem; the customer base, US FDA-standard facilities, and audits remain the same. Most MCC manufacturers also have CCS as an additional product.
Joint Ventures & International Expansion
- MENA joint venture: A joint venture with Saudi partner SNP (Saudi National Projects and Investments) is in place, described as a very ambitious project.
- Additional joint ventures: Management has signed certain joint ventures with international parties over the last 1-2 months.
Sinha: "The joint venture with our Saudi partner SNP (Saudi National Projects and Investments) is a very ambitious project with a very ambitious and good partner of Saudi."
Capacity Expansion & CapEx
- MCC plant expansion: Commissioning activities to commence by end of Q3 FY24; sales will show on the balance sheet in Q4.
- CCS expansion: Environmental clearance expected by December 2023, a slight delay from November; civil works commence immediately after. Design, vendors, and everything else is ready; purchase orders and advances will be issued immediately upon clearance.
- API subsidiary CapEx: Additional CapEx investment is planned for increasing capacities but will not commence now; management wants to stabilize existing operations first, with CapEx expected to start in another three months.
- Hyderabad plant modernization: An ongoing process that continues round the year; no new production blocks are being added.
- Kurnool spare land: Management looks for opportunities and jumps in even with ambiguity, stating they do not wait for perfect situations before taking the first step.
Sinha: "We don't wait for a perfect situation for taking the first step. We look out for opportunities and jump in into opportunities even if there is a bit of ambiguity because when the ambiguity clears and when the things are crystal clear, there will be big players who would have already been kilometers ahead of us."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY24 revenue | ₹400 crores | FY24 |
| API revenue | ~₹60 crores | FY24 |
| MCC expansion commissioning | Commissioning activities commence | End of Q3 FY24 |
| MCC expansion sales contribution | 25% of added capacity | Q4 FY24 |
| Employee cost stabilization | Stabilization begins | Q4 FY24 onward |
| CCS environmental clearance | Clearance received | December 2023 |
| CCS commissioning | 18 months from clearance | ~Mid-2025 |
| API subsidiary CapEx | Additional CapEx commences | ~3 months from now |
| Top-line growth (excipient business) | 25% increase | Current running business |
| 3-5 year top-line growth | At least 25% year-on-year | Next 3 to 5 years |
| EBITDA margin | Positive side of 20% | All throughout |
Sinha: "I'm looking at at least a 25% growth year-on-year over the next 3 to 5 years."
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Operating income | ₹99 cr, +20.2% YoY |
| EBITDA | ₹21 cr, +31.2% YoY |
| EBITDA margin | 21.57% |
| Net profit | ~₹15 cr, +11% YoY |
| PAT margin | 15.22% |
| H1 FY24 operating income | ~₹184 cr, +14.4% YoY |
| H1 FY24 EBITDA | ₹37.8 cr, +16% YoY |
| H1 FY24 EBITDA margin | 20.55% |
| H1 FY24 net profit | ₹26 cr, -1.5% YoY |
| H1 FY24 PAT margin | 14.14% |
| H1 FY24 overall revenue | ₹186.62 cr, +13.37% YoY from ₹164.61 cr |
| MCC price H1 FY24 | ₹210.8/Kg, +1.07% YoY from ₹208.55/Kg |
| MCC quantity H1 FY24 | 7,307 MT, +3.63% YoY from 7,051 MT |
| Sale of products H1 FY24 | ₹166.46 cr, from ₹149.95 cr in H1 FY23 |
| Employee cost | ₹14.73 cr, up from ~₹12.8 cr in Q1 FY24 |
| API subsidiary top line (Aug–Sep) | ~₹7.5 cr, since acquisition on 1 Aug 2023 |
| Total capacities | >13,800 tonnes per annum, being enhanced to ~21,000 MTPA |
| FY24 revenue guidance | ₹400 cr, maintained |
| 7,000 MTPA CapEx ramp-up | 25% of added capacity targeted in Q4 FY24; 10% in Q3 not expected |
| Other current liabilities H1 FY24 | ₹118 cr, up from ₹9.4 cr due to provision for Trimax acquisition consideration |
| Medium-term top-line growth target | At least 25% YoY over the next 3 to 5 years |